Helen Louise Collins

CIK: 0001701247

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)26 (59.1%)

Position reduction

Option Exercises (M)13 (29.5%)

Derivative conversions

Awards (A)5 (11.4%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

ELVN

Enliven Therapeutics, Inc.

Officer

KURA

Kura Oncology, Inc.

Director

IOBT

IO Biotech, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (44 total)

ELVN
Enliven Therapeutics, Inc.
Oct 19, 2026
Exercise(M)
Direct
5K shares at avg. $2.48$12K
ELVN
Enliven Therapeutics, Inc.
Oct 19, 2026
Sale(S)
Direct
5K shares at avg. $38.47$192K
ELVN
Enliven Therapeutics, Inc.
Sep 17, 2026
Exercise(M)
Direct
5K shares at avg. $2.48$12K
ELVN
Enliven Therapeutics, Inc.
Sep 17, 2026
Sale(S)
Direct
2.9K shares at avg. $50.03$146K
ELVN
Enliven Therapeutics, Inc.
Sep 17, 2026
Sale(S)
Direct
240 shares at avg. $51.48$12K
ELVN
Enliven Therapeutics, Inc.
Sep 17, 2026
Sale(S)
Direct
1.8K shares at avg. $50.71$94K
ELVN
Enliven Therapeutics, Inc.
Aug 17, 2026
Exercise(M)
Direct
5K shares at avg. $2.48$12K
ELVN
Enliven Therapeutics, Inc.
Aug 17, 2026
Sale(S)
Direct
3.9K shares at avg. $58.37$228K
ELVN
Enliven Therapeutics, Inc.
Aug 17, 2026
Sale(S)
Direct
1.1K shares at avg. $59.35$65K
ELVN
Enliven Therapeutics, Inc.
Jul 17, 2026
Sale(S)
Direct
2.1K shares at avg. $52.39$108K
ELVN
Enliven Therapeutics, Inc.
Jul 17, 2026
Sale(S)
Direct
2.2K shares at avg. $53.42$117K
ELVN
Enliven Therapeutics, Inc.
Jul 17, 2026
Sale(S)
Direct
63 shares at avg. $53.92$3K
ELVN
Enliven Therapeutics, Inc.
Jul 17, 2026
Sale(S)
Direct
231 shares at avg. $50.05$12K
ELVN
Enliven Therapeutics, Inc.
Jul 17, 2026
Sale(S)
Direct
459 shares at avg. $51.55$24K
ELVN
Enliven Therapeutics, Inc.
Jul 17, 2026
Exercise(M)
Direct
5K shares at avg. $2.48$12K
ELVN
Enliven Therapeutics, Inc.
Jun 17, 2026
Sale(S)
Direct
1.1K shares at avg. $44.74$51K
ELVN
Enliven Therapeutics, Inc.
Jun 17, 2026
Sale(S)
Direct
2.6K shares at avg. $43.87$114K
ELVN
Enliven Therapeutics, Inc.
Jun 17, 2026
Sale(S)
Direct
1.3K shares at avg. $42.83$54K
ELVN
Enliven Therapeutics, Inc.
Jun 17, 2026
Exercise(M)
Direct
5K shares at avg. $2.48$12K
KURA
Kura Oncology, Inc.
Jun 4, 2026
Award(A)
Option to purchase common stock
Direct
35K shares-
ELVN
Enliven Therapeutics, Inc.
May 18, 2026
Sale(S)
Direct
1.3K shares at avg. $40.25$52K
ELVN
Enliven Therapeutics, Inc.
May 18, 2026
Exercise(M)
Direct
5K shares at avg. $2.48$12K
ELVN
Enliven Therapeutics, Inc.
May 18, 2026
Sale(S)
Direct
223 shares at avg. $41.21$9K
ELVN
Enliven Therapeutics, Inc.
May 18, 2026
Sale(S)
Direct
3.5K shares at avg. $39.53$137K
ELVN
Enliven Therapeutics, Inc.
Apr 17, 2026
Sale(S)
Direct
2.4K shares at avg. $47.39$115K

		Type	Shares	Price		Ownership
Oct 19, 2026	ELVN Enliven Therapeutics, Inc.	Exercise(M)	5,000	$2.48	$12,400	Direct
Oct 19, 2026	ELVN Enliven Therapeutics, Inc.	Sale(S)	5,000	$38.47	$192,342	Direct
Sep 17, 2026	ELVN Enliven Therapeutics, Inc.	Exercise(M)	5,000	$2.48	$12,400	Direct
Sep 17, 2026	ELVN Enliven Therapeutics, Inc.	Sale(S)	2,916	$50.03	$145,891	Direct
Sep 17, 2026	ELVN Enliven Therapeutics, Inc.	Sale(S)	240	$51.48	$12,356	Direct
Sep 17, 2026	ELVN Enliven Therapeutics, Inc.	Sale(S)	1,844	$50.71	$93,507	Direct
Aug 17, 2026	ELVN Enliven Therapeutics, Inc.	Exercise(M)	5,000	$2.48	$12,400	Direct
Aug 17, 2026	ELVN Enliven Therapeutics, Inc.	Sale(S)	3,900	$58.37	$227,650	Direct
Aug 17, 2026	ELVN Enliven Therapeutics, Inc.	Sale(S)	1,100	$59.35	$65,281	Direct
Jul 17, 2026	ELVN Enliven Therapeutics, Inc.	Sale(S)	2,063	$52.39	$108,085	Direct
Jul 17, 2026	ELVN Enliven Therapeutics, Inc.	Sale(S)	2,184	$53.42	$116,669	Direct
Jul 17, 2026	ELVN Enliven Therapeutics, Inc.	Sale(S)	63	$53.92	$3,397	Direct
Jul 17, 2026	ELVN Enliven Therapeutics, Inc.	Sale(S)	231	$50.05	$11,563	Direct
Jul 17, 2026	ELVN Enliven Therapeutics, Inc.	Sale(S)	459	$51.55	$23,660	Direct
Jul 17, 2026	ELVN Enliven Therapeutics, Inc.	Exercise(M)	5,000	$2.48	$12,400	Direct
Jun 17, 2026	ELVN Enliven Therapeutics, Inc.	Sale(S)	1,133	$44.74	$50,694	Direct
Jun 17, 2026	ELVN Enliven Therapeutics, Inc.	Sale(S)	2,599	$43.87	$114,018	Direct
Jun 17, 2026	ELVN Enliven Therapeutics, Inc.	Sale(S)	1,268	$42.83	$54,305	Direct
Jun 17, 2026	ELVN Enliven Therapeutics, Inc.	Exercise(M)	5,000	$2.48	$12,400	Direct
Jun 4, 2026	KURA Kura Oncology, Inc.	Award(A) Option to purchase common stock	35,000	-	-	Direct
May 18, 2026	ELVN Enliven Therapeutics, Inc.	Sale(S)	1,302	$40.25	$52,402	Direct
May 18, 2026	ELVN Enliven Therapeutics, Inc.	Exercise(M)	5,000	$2.48	$12,400	Direct
May 18, 2026	ELVN Enliven Therapeutics, Inc.	Sale(S)	223	$41.21	$9,189	Direct
May 18, 2026	ELVN Enliven Therapeutics, Inc.	Sale(S)	3,475	$39.53	$137,381	Direct
Apr 17, 2026	ELVN Enliven Therapeutics, Inc.	Sale(S)	2,419	$47.39	$114,635	Direct

1-25 of 44 transactions

About Collins Helen Louise

Collins Helen Louise (SEC CIK 0001701247) files insider reports with the SEC as CHIEF MEDICAL OFFICER of Enliven Therapeutics, Inc. (ELVN), Director of Kura Oncology, Inc. (KURA) and Director of IO Biotech, Inc. (IOBT).

Signal8 holds 17 ownership filings by Collins Helen Louise, all Form 4s, filed between Oct 22, 2024 and Oct 21, 2026. Those filings report 44 transactions, from Oct 18, 2024 to Oct 19, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Collins Helen Louise's filings is in BURLINGAME, CA.

Recent filings by Collins Helen Louise

Oct 19, 2026: Option exercise of ELVN shares (Form 4, code M).
Oct 19, 2026: Open-market sale of ELVN shares (Form 4, code S).
Sep 17, 2026: Option exercise of ELVN shares (Form 4, code M).
Sep 17, 2026: Open-market sales of ELVN shares (3 lines, Form 4, code S).
Aug 17, 2026: Option exercise of ELVN shares (Form 4, code M).

Other insiders filing for Enliven Therapeutics, Inc. (ELVN)

Kunkel Lori Anne, Officer
Hohl Benjamin, CHIEF FINANCIAL OFFICER
BALL KRISTINE M, Director
Garland J. Scott, Director
Derynck Mika K, Director
ORBIMED ADVISORS LLC, 10% Owner

How to read Form 4 transaction codes